Abstracts tagged "work"

Abstract Number: 1866 • ACR Convergence 2020
Patient-reported Impact of Axial Spondyloarthritis on Working Life. Results from the Spanish Atlas 2017
Marco Garrido-Cumbrera¹, Eduardo Collantes-Estévez², Victoria Navarro-Compán³, Pedro Zarco⁴, Carlos Sastre⁵, Sergio Sanz-Gomez⁶, José Correa-Fernández⁷ and Jordi Gratacós⁸, ¹Health & Territory Research (HTR), Universidad de Sevilla / Spanish Federation of Spondyloarthritis Associations, Sevilla, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ³Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁴Novartis Farmacéutica Spain, Alcorcon, Madrid, Spain, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Health & Territory Research, Seville, Spain, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Sevilla, Spain, ⁸University Hospital Parc Tauli Sabadell, Barcelona, Spain
Background/Purpose: Axial spondyloarthritis (axSpA) impacts negatively on multiple dimensions of patient’s life, including their working life. The present study aims to evaluate working status, work-related…
Abstract Number: 1871 • ACR Convergence 2020
Comparison of Work Productivity Outcomes Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-Up: Data from the Spondyloarthritis Caught Early Cohort
Anne Boel¹, Miranda van Lunteren², Karen Fagerli³, Roberta Ramonda⁴, Sofia Exarchou⁵, Marleen van de Sande⁶, Floris van Gaalen⁷ and Désirée van der Heijde⁸, ¹Leiden University Medical Centre, Hooge Zwaluwe, Netherlands, ²Leiden University Medical Centre, Weesp, Netherlands, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴University of Padova, Padova, Italy, ⁵Rheumatology, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden, Malmo, Sweden, ⁶Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Leiden University Medical Center (LUMC), Leiden, Netherlands, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The aim of this study was to compare work-productivity and activity impairment outcomes after two-year follow-up between chronic back pain (CBP) patients with and…
Abstract Number: 0141 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results from FINCH-1 Study
Zobair Younossi¹, Maria Stepanova², Lynn Gerber¹, Susan Lee³, Hao Hu³, Thijs Hendrikx⁴, Annelies Boonen⁵, David Walker⁶, Rieke Alten⁷ and Bernard Combe⁸, ¹Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, ²Center for Outcomes Research in Liver Disease, Washington, DC, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵Maastricht University Medical Center, Maastricht, Netherlands, ⁶Northumbria Healthcare Trust, North Shields, United Kingdom, ⁷Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ⁸University of Montpellier, Montpellier, France
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor which is currently being investigated as an agent to treat rheumatoid arthritis (RA).…
Abstract Number: 0142 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs: Results from the FINCH 2 Study
Zobair Younossi¹, Maria Stepanova², Lynn Gerber¹, Susan Lee³, I-Heng Lee⁴, Thijs Hendrikx⁵, Annelies Boonen⁶, Rieke Alten⁷, Bernard Combe⁸ and David Walker⁹, ¹Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, ²Center for Outcomes Research in Liver Disease, Washington, DC, ³Gilead Sciences, Inc., Foster City, CA, ⁴Gilead Sciences, Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶Maastricht University Medical Center, Maastricht, Netherlands, ⁷Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ⁸University of Montpellier, Montpellier, France, ⁹Northumbria Healthcare Trust, North Shields, United Kingdom
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor which is currently being investigated as an agent to treat rheumatoid arthritis (RA).…
Abstract Number: 0143 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis Who Are Methotrexate-naïve: Results from the FINCH-3 Study
Zobair Younossi¹, Maria Stepanova², Lynn Gerber¹, Susan Lee³, Ken Hasegawa³, Thijs Hendrikx⁴, Annelies Boonen⁵, Bernard Combe⁶, David Walker⁷ and Rieke Alten⁸, ¹Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, ²Center for Outcomes Research in Liver Disease, Washington, DC, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵Maastricht University Medical Center, Maastricht, Netherlands, ⁶University of Montpellier, Montpellier, France, ⁷Northumbria Healthcare Trust, North Shields, United Kingdom, ⁸Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor currently being investigated as an agent to treat rheumatoid arthritis (RA). In the…
Abstract Number: 0165 • ACR Convergence 2020
Work Disability and Predictors of Poor Work Outcome in Patients with Axial Spondyloarthritis
Elif Ediboglu¹, Dilek Solmaz², Hande Ece Oz³, Gokhan Kabadayı⁴, Haluk Cinaklı⁴, Eda Otman Akat³, Mustafa Ozmen⁴ and Servet Akar³, ¹Izmir Katip Celebi University, Izmir, Izmir, Turkey, ²Izmir Katip Celebi University, Department of Internal Medicine, Division of Rheumatology, Izmir, TURKEY, Izmir, Turkey, ³Izmir Katip Celebi University, Izmir, Turkey, ⁴Izmir Katip Celebi University, Izmir
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which may lead substantial functional limitation. The disease more commonly affects men in their third decade…
Abstract Number: 0326 • ACR Convergence 2020
Flares Among Patients with Psoriatic Arthritis (PsA) – Frequency and Impact on Patient Outcomes: Real-world Survey in the US and Europe
Ana-Maria Orbai¹, William Tillett², Suzann Grieb³, James Piercy⁴, Steven Peterson⁵, Elizabeth Holdsworth⁴, Sophie Meakin⁴, Soumya Chakravarty⁶, Nicola Booth⁴ and Laure Gossec⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ³John Hopkins University School of Medicine, Baltimore, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France
Background/Purpose: Flares in PsA, presenting as periods of acute disease activity, are thought to negatively impact patients’ lives. This has not been extensively studied in…
Abstract Number: 0331 • ACR Convergence 2020
Work Absenteeism and Disability Associated with Psoriatic Arthritis and Psoriasis in the United States – A Retrospective Study of Claims Data from 2009 to 2020
Ana-Maria Orbai¹, Soumya Reddy², Steven Peterson³, Natalie Dennis⁴, Reginald Villacorta⁵, Laura Mesana⁶, Soumya Chakravarty⁷, Maud Pacou⁴, Iris Lin⁵, Thomas Baker⁸, Yiting Wang⁹ and Jessica Walsh¹⁰, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²NYU School of Medicine, New York City, ³Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁴Amaris, Paris, France, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, ⁶Amaris, New York, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁸Janssen Global Services, LLC, Raritan, NJ, ⁹Janssen R&D, LLC, Titusville, ¹⁰University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Absenteeism and work disability substantially contribute to the economic burden of psoriasis and psoriatic arthritis (PsA). This study compared work absenteeism and short-term disability…
Abstract Number: 0332 • ACR Convergence 2020
Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
Jeffrey R Curtis¹, Iain McInnes², Proton Rahman³, William Tillett⁴, Philip Mease⁵, Alexa Kollmeier⁶, Elizabeth Hsia⁷, Bei Zhou⁸, Prasheen Agarwal⁸, Steven Peterson⁹ and Chenglong Han⁸, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁶Janssen Research & Development, LLC, La Jolla, CA, ⁷Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Janssen Immunology Global Commercial Strategy Organization, Horsham, PA
Background/Purpose: DISCOVER 2 (DISC 2) is a Phase 3 trial of anti-IL-23-specific MAb Guselkumab (GUS) in PsA patients, who experience impaired physical function, resulting in…
Abstract Number: 2085 • 2019 ACR/ARP Annual Meeting
Too Soon to Say: Promising Results from a Community-Delivered RCT Examining Work-Related Outcomes of the Chronic Disease Self-Management Program
Kristina Theis¹, Teresa Brady ² and Shawn Kneipp ³, ¹Centers for Disease Control and Prevention, Atlanta, ²Clarity Consulting and Communications, Atlanta, GA, ³School of Nursing, The University of North Carolina at Chapel Hill, Atlanta, GA
Background/Purpose: More than two-thirds of U.S. adults with arthritis are working-age (< 65), and arthritis is a leading cause of work disability. The Chronic Disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].